{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T09:28:43Z","timestamp":1786786123562,"version":"build-2736575974"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"J&J Innovative Medicine EMEA"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    For younger, fit patients with mantle cell lymphoma (MCL), first-line therapy includes high-dose chemotherapy (HDCT) and autologous stem cell transplantation (ASCT). HDCT-ASCT demands considerable healthcare resources and costs and causes acute and long-term complications. The phase 3 TRIANGLE trial found clinically beneficial improvements in overall survival and safety when HDCT-ASCT was replaced with an ibrutinib regimen without ASCT. This study aimed to develop a comprehensive ASCT treatment clinical pathway model for patients newly diagnosed with MCL and assess the impact on hospitalization duration, healthcare resources, and cost. The clinical pathway was modeled using ClipMed\n                    <jats:sup>\u00ae<\/jats:sup>\n                    PPM software-based process analysis. Data were sourced from the IWiG\n                    <jats:sup>\u00ae<\/jats:sup>\n                    reference model for quantitative activity-based health economic evaluation and validated by clinical experts alongside standard operating procedures. Cost inputs were obtained using reimbursement sources and tariff publications in Germany. The total clinical pathway, from ASCT-eligibility assessments, induction therapy, HDCT-ASCT consolidation, and up to 100 days post-ASCT, covered: 49 patient-clinician interaction days; 346 patient services (inpatient and outpatient settings); 1653 processes. HDCT-ASCT involved 23 days\u2019 hospitalization. Healthcare professionals\u2019 time associated with apheresis and HDCT-ASCT, which could be spared with the TRIANGLE ibrutinib regimen without ASCT, totaled 214\u00a0h. Costs associated with the total clinical pathway, excluding those associated with severe adverse events, other comorbidities, and long-term complications, amounted to \u20ac50,815 per patient. For newly diagnosed ASCT-eligible patients with MCL, HDCT-ASCT is associated with at least 23 hospitalization days, considerable costs, and substantial healthcare resources \u2013 assets that could be redirected with adoption of the TRIANGLE ibrutinib regimen without ASCT.\n                  <\/jats:p>","DOI":"10.1007\/s00277-026-07139-1","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T10:46:34Z","timestamp":1784198794000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Healthcare resource utilization analysis in newly diagnosed mantle cell lymphoma: resource alleviation with adoption of the TRIANGLE ibrutinib regimen without autologous stem cell transplantation"],"prefix":"10.1007","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-3635-1036","authenticated-orcid":false,"given":"Jonas","family":"Wi\u00dfkirchen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3914-4747","authenticated-orcid":false,"given":"Nora S.","family":"Rogmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3449-5123","authenticated-orcid":false,"given":"Michael","family":"Greiling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4105-1771","authenticated-orcid":false,"given":"Frederic","family":"Ries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4036-4744","authenticated-orcid":false,"given":"Anke","family":"Ohler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9282-5688","authenticated-orcid":false,"given":"Georg","family":"Hess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3068-6009","authenticated-orcid":false,"given":"Julia","family":"Osygus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,16]]},"reference":[{"issue":"5","key":"7139_CR1","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1080\/03007995.2020.1742101","volume":"36","author":"N Monga","year":"2020","unstructured":"Monga N, Garside J, Quigley J et al (2020) Systematic literature review of the global burden of illness of mantle cell lymphoma. Curr Med Res Opin 36(5):843\u2013852. https:\/\/doi.org\/10.1080\/03007995.2020.1742101","journal-title":"Curr Med Res Opin"},{"issue":"6","key":"7139_CR2","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3322\/caac.21357","volume":"66","author":"LR Teras","year":"2016","unstructured":"Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A, Flowers CR (2016) 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin 66(6):443\u2013459. https:\/\/doi.org\/10.3322\/caac.21357","journal-title":"CA Cancer J Clin"},{"key":"7139_CR3","unstructured":"National Cancer Institute Surveillance (2025) Epidemiology, and End Results (SEER) Cancer Statistics Review, 1975\u20132017. Accessed August 7 https:\/\/seer.cancer.gov\/archive\/csr\/1975_2017\/results_merged\/sect_19_nhl.pdf. Accessed 7 Aug"},{"key":"7139_CR4","unstructured":"The Haematological Malignancy Research Network (2022) Factsheets: Mantle cell lymphoma https:\/\/hmrn.org\/factsheets#mantle_cell_lymphoma. Accessed 7 Aug 2025"},{"key":"7139_CR5","doi-asserted-by":"publisher","first-page":"102513","DOI":"10.1016\/j.canep.2023.102513","volume":"88","author":"M Lamb","year":"2024","unstructured":"Lamb M, Painter D, Howell D et al (2024) Lymphoid blood cancers, incidence and survival 2005\u20132023: a report from the UK\u2019s Haematological Malignancy Research Network. Cancer Epidemiol 88:102513. https:\/\/doi.org\/10.1016\/j.canep.2023.102513","journal-title":"Cancer Epidemiol"},{"issue":"17","key":"7139_CR6","doi-asserted-by":"publisher","first-page":"4388","DOI":"10.3390\/cancers15174388","volume":"15","author":"K Henau","year":"2023","unstructured":"Henau K, Tambuyzer T, Van Gool B, Van Eycken L, Poirel HA (2023) Epidemiological trends of haematological malignancies in Belgium 2004\u20132018: older patients show the greatest improvement in survival. Cancers (Basel) 15(17):4388. https:\/\/doi.org\/10.3390\/cancers15174388","journal-title":"Cancers (Basel)"},{"issue":"9","key":"7139_CR7","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1038\/bjc.2015.94","volume":"112","author":"A Smith","year":"2015","unstructured":"Smith A, Crouch S, Lax S, Li J, Painter D, Howell D, Patmore R, Jack A, Roman E (2015) Lymphoma incidence, survival and prevalence 2004\u20132014: sub-type analyses from the UK\u2019s Haematological Malignancy Research Network. Br J Cancer 112(9):1575\u20131584. https:\/\/doi.org\/10.1038\/bjc.2015.94","journal-title":"Br J Cancer"},{"issue":"17","key":"7139_CR8","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1182\/blood-2017-04-779736","volume":"130","author":"CW Eskelund","year":"2017","unstructured":"Eskelund CW, Dahl C, Hansen JW et al (2017) TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. Blood 130(17):1903\u20131910. https:\/\/doi.org\/10.1182\/blood-2017-04-779736","journal-title":"Blood"},{"issue":"suppl4","key":"7139_CR9","doi-asserted-by":"publisher","first-page":"iv62","DOI":"10.1093\/annonc\/mdx223","volume":"28","author":"M Dreyling","year":"2017","unstructured":"Dreyling M, Campo E, Hermine O et al (2017) Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 28(suppl4):iv62\u2013iv71. https:\/\/doi.org\/10.1093\/annonc\/mdx223","journal-title":"Ann Oncol"},{"key":"7139_CR10","unstructured":"Dreyling M, Buske C, Cairoli A, He\u00df G, Hoster E, Mey UJM, Nowak M, Pott C, Raderer M (2023) Onkopedia. Mantelzell-Lymphom. June 2023 https:\/\/www.onkopedia.com\/de\/onkopedia\/guidelines\/mantelzell-lymphom\/@@guideline\/html\/index.html. Accessed August 7, 2025"},{"issue":"11","key":"7139_CR11","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1016\/j.bbmt.2017.07.006","volume":"23","author":"MG Mei","year":"2017","unstructured":"Mei MG, Cao TM, Chen L et al (2017) Long-term results of high-dose therapy and autologous stem cell transplantation for mantle cell lymphoma: effectiveness of maintenance rituximab. Biol Blood Marrow Transpl 23(11):1861\u20131869. https:\/\/doi.org\/10.1016\/j.bbmt.2017.07.006","journal-title":"Biol Blood Marrow Transpl"},{"issue":"11","key":"7139_CR12","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.3324\/haematol.2021.280413","volume":"107","author":"K Smeland","year":"2022","unstructured":"Smeland K, Holte H, Fagerli UM et al (2022) Total late effect burden in long-term lymphoma survivors after high-dose therapy with autologous stem-cell transplant and its effect on health-related quality of life. Haematologica 107(11):2698\u20132707. https:\/\/doi.org\/10.3324\/haematol.2021.280413","journal-title":"Haematologica"},{"issue":"11","key":"7139_CR13","doi-asserted-by":"publisher","first-page":"3090","DOI":"10.3109\/10428194.2015.1034700","volume":"56","author":"L Kerhuel","year":"2015","unstructured":"Kerhuel L, Amorim S, Azoulay E, Thieblemont C, Canet E (2015) Clinical features of life-threatening complications following autologous stem cell transplantation in patients with lymphoma. Leuk Lymphoma 56(11):3090\u20133095. https:\/\/doi.org\/10.3109\/10428194.2015.1034700","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"7139_CR14","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1007\/s00277-021-04650-5","volume":"100","author":"R Wullenkord","year":"2021","unstructured":"Wullenkord R, Berning P, Niemann AL et al (2021) The role of autologous stem cell transplantation (ASCT) in aggressive B-cell lymphomas: real-world data from a retrospective single-center analysis. Ann Hematol 100(11):2733\u20132744. https:\/\/doi.org\/10.1007\/s00277-021-04650-5","journal-title":"Ann Hematol"},{"issue":"6","key":"7139_CR15","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1182\/bloodadvances.2020003645","volume":"5","author":"I Glimelius","year":"2021","unstructured":"Glimelius I, Smedby KE, Albertsson-Lindblad A, Crowther MJ, Eloranta S, Jerkeman M, Weibull CE (2021) Unmarried or less-educated patients with mantle cell lymphoma are less likely to undergo a transplant, leading to lower survival. Blood Adv 5(6):1638\u20131647. https:\/\/doi.org\/10.1182\/bloodadvances.2020003645","journal-title":"Blood Adv"},{"issue":"12","key":"7139_CR16","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1002\/cam4.543","volume":"4","author":"TA Alwasaidi","year":"2015","unstructured":"Alwasaidi TA, Hamadah A, Altouri S et al (2015) Outcomes of both abbreviated hyper-CVAD induction followed by autologous hematopoietic cell transplantation and conventional chemotherapy for mantle cell lymphoma: a 10-year single-centre experience with literature review. Cancer Med 4(12):1817\u20131827. https:\/\/doi.org\/10.1002\/cam4.543","journal-title":"Cancer Med"},{"issue":"2","key":"7139_CR17","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s00277-017-3180-x","volume":"97","author":"F Widmer","year":"2018","unstructured":"Widmer F, Balabanov S, Soldini D, Samaras P, Gerber B, Manz MG, Goede JS (2018) R-hyper-CVAD versus R-CHOP\/cytarabine with high-dose therapy and autologous haematopoietic stem cell support in fit patients with mantle cell lymphoma: 20 years of single-center experience. Ann Hematol 97(2):277\u2013287. https:\/\/doi.org\/10.1007\/s00277-017-3180-x","journal-title":"Ann Hematol"},{"issue":"1","key":"7139_CR18","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s00277-022-05028-x","volume":"102","author":"J Garcia Borrega","year":"2023","unstructured":"Garcia Borrega J, Boll B, Kochanek M et al (2023) Characteristics and outcomes of patients undergoing high-dose chemotherapy and autologous stem cell transplantation admitted to the intensive care unit: a single-center retrospective analysis. Ann Hematol 102(1):191\u2013197. https:\/\/doi.org\/10.1007\/s00277-022-05028-x","journal-title":"Ann Hematol"},{"issue":"2","key":"7139_CR19","doi-asserted-by":"publisher","first-page":"121","DOI":"10.2217\/cer-2018-0100","volume":"8","author":"L Mayerhoff","year":"2019","unstructured":"Mayerhoff L, Lehne M, Hickstein L, Salimullah T, Prieur S, Thomas SK, Zhang J (2019) Cost associated with hematopoietic stem cell transplantation: a retrospective claims data analysis in Germany. J Comp Eff Res 8(2):121\u2013131. https:\/\/doi.org\/10.2217\/cer-2018-0100","journal-title":"J Comp Eff Res"},{"issue":"Suppl 1","key":"7139_CR20","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1182\/blood-2024-200735","volume":"144","author":"M Dreyling","year":"2024","unstructured":"Dreyling M, Doorduijn JK, Gine E et al (2024) Role of autologous stem cell transplantation in the context of ibrutinib-containing first-line treatment in younger patients with mantle cell lymphoma: results from the randomized TRIANGLE trial by the European MCL Network. Blood 144(Suppl 1):240","journal-title":"Blood"},{"issue":"10441","key":"7139_CR21","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1016\/S0140-6736(24)00184-3","volume":"403","author":"M Dreyling","year":"2024","unstructured":"Dreyling M, Doorduijn J, Gine E et al (2024) Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network. Lancet 403(10441):2293\u20132306. https:\/\/doi.org\/10.1016\/S0140-6736(24)00184-3","journal-title":"Lancet"},{"issue":"10542","key":"7139_CR22","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1016\/S0140-6736(26)00362-4","volume":"407","author":"M Dreyling","year":"2026","unstructured":"Dreyling M, Doorduijn J, Gin\u00e9 E et al (2026) Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18\u201365 years with mantle cell lymphoma (TRIANGLE): 4\u00b75-year follow-up of a three-arm, randomised,open-label, phase 3 superiority trial of the European MCL Network. Lancet 407(10542):1953\u20131967. https:\/\/doi.org\/10.1016\/S0140-6736(26)00362-4","journal-title":"Lancet"},{"issue":"1","key":"7139_CR23","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/bjh.19131","volume":"204","author":"TA Eyre","year":"2024","unstructured":"Eyre TA, Bishton MJ, McCulloch R et al (2024) Diagnosis and management of mantle cell lymphoma: a British Society for Haematology Guideline. Br J Haematol 204(1):108\u2013126. https:\/\/doi.org\/10.1111\/bjh.19131","journal-title":"Br J Haematol"},{"key":"7139_CR24","unstructured":"Lymphoma.cz (2024) ) Diagnostick\u00e9 a l\u00e9\u010debn\u00e9 postupy u nemocn\u00fdch s malign\u00edmi lymfomy - XIV. vyd\u00e1n\u00ed. https:\/\/www.lymphoma.cz\/_uploads\/attachments\/KLS_guidelines_2024_final_1.pdf. Accessed 11 Aug 2025"},{"key":"7139_CR25","unstructured":"Onco-Occitanie (2025) Lymphomes Chez L\u2019Adulte. https:\/\/www.calameo.com\/onco-occitanie\/read\/007178092faf625aec914. Accessed 11 Aug 2025"},{"issue":"20","key":"7139_CR26","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1200\/jco-25-00146","volume":"43","author":"TA Eyre","year":"2025","unstructured":"Eyre TA, Cheah CY, Sarkozy C, Kumar A, Le Gouill S (2025) Mantle cell lymphoma: Optimal treatment with Bruton tyrosine kinase\u2013targeted approaches. J Clin Oncol 43(20):2300\u20132310. https:\/\/doi.org\/10.1200\/jco-25-00146","journal-title":"J Clin Oncol"},{"key":"7139_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.07.014","author":"TA Eyre","year":"2025","unstructured":"Eyre TA, Cwynarski K, d\u2019Amore F et al (2025) Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. https:\/\/doi.org\/10.1016\/j.annonc.2025.07.014","journal-title":"Ann Oncol"},{"key":"7139_CR28","unstructured":"European Medicines Agency (2025) IMBRUVICA Summary of Product Characteristics. September 2024. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/imbruvica-epar-product-information_en.pdf. Accessed 8 Aug 2025"},{"key":"7139_CR29","unstructured":"European Medicines Agency (2025) IMBRUVICA. Summary of opinion (post authorisation). July 2025. https:\/\/www.ema.europa.eu\/en\/documents\/smop\/chmp-post-authorisation-summary-positive-opinion-imbruvica-ii-92_en.pdf. Accessed 8 Aug 2025"},{"key":"7139_CR30","unstructured":"Institut f\u00fcr Workflow-Management im Gesundheitswesen (IWiG) (2025) ClipMed PPM. The Path and Process Cost Manager. https:\/\/iwig-institut.de\/clipmed-ppm\/. Accessed 11 Aug"},{"key":"7139_CR31","unstructured":"Greiling M (2019) Workflow-Management Exzellenz-Modell - Eine Erfolgsstrategie f\u00fcr mehr Zeit durch weniger Verschwendung. Wege zur Effektivit\u00e4t, Mediengruppe Oberfranken., vol vol. Band 2;. Wege zur Effektivit\u00e4t, Mediengruppe Oberfranken"},{"key":"7139_CR32","unstructured":"Institut f\u00fcr das Entgeltsystem im Krankenhaus (InEK) (2012) Vereinbarung \u00fcber die Teilnahme an der Kalkulation von Investitionskosten in Krankenh\u00e4usern f\u00fcr Zwecke gem. \u00a7 10 KHG. http:\/\/www.g-drg.de\/cms\/Kalkulation2\/Investitionskosten\/Vereinbarung. Accessed 6 Oct 2025"},{"issue":"2","key":"7139_CR33","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s41669-020-00231-w","volume":"5","author":"N Monga","year":"2021","unstructured":"Monga N, Garside J, Davids MS, Tam C, Ward K, Fotheringham I, O\u2019Donovan P, Parisi L, Tapprich C (2021) Systematic literature review of economic evaluations, costs\/resource use, and quality of life in patients with mantle cell lymphoma. Pharmacoecon Open 5(2):175\u2013186. https:\/\/doi.org\/10.1007\/s41669-020-00231-w","journal-title":"Pharmacoecon Open"},{"key":"7139_CR34","doi-asserted-by":"publisher","first-page":"q8","DOI":"10.1136\/bmj.q8","volume":"384","author":"MK Looi","year":"2024","unstructured":"Looi MK (2024) The European healthcare workforce crisis: how bad is it? BMJ 384:q8. https:\/\/doi.org\/10.1136\/bmj.q8","journal-title":"BMJ"},{"issue":"3","key":"7139_CR35","doi-asserted-by":"publisher","first-page":"2624","DOI":"10.1002\/cam4.5139","volume":"12","author":"MW Parsons","year":"2023","unstructured":"Parsons MW, Rock C, Chipman JJ, Shah HR, Hu B, Stephens DM, Tao R, Tward JD, Gaffney DK (2023) Secondary malignancies in non-Hodgkin lymphoma survivors: 40 years of follow-up assessed by treatment modality. Cancer Med 12(3):2624\u20132636. https:\/\/doi.org\/10.1002\/cam4.5139","journal-title":"Cancer Med"},{"issue":"10","key":"7139_CR36","doi-asserted-by":"publisher","first-page":"e838","DOI":"10.1016\/s2352-3026(23)00212-0","volume":"10","author":"T Trab","year":"2023","unstructured":"Trab T, Baech J, Jakobsen LH et al (2023) Second primary malignancies in patients with lymphoma in Denmark after high-dose chemotherapy and autologous haematopoietic stem-cell transplantation: a population-based, retrospective cohort study. Lancet Haematol 10(10):e838\u2013e848. https:\/\/doi.org\/10.1016\/s2352-3026(23)00212-0","journal-title":"Lancet Haematol"},{"issue":"1","key":"7139_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jinf.2022.11.005","volume":"86","author":"PDE Miller","year":"2023","unstructured":"Miller PDE, Patel SR, Skinner R et al (2023) Joint consensus statement on the vaccination of adult and paediatric haematopoietic stem cell transplant recipients: prepared on behalf of the British Society of Blood and Marrow Transplantation and Cellular Therapy (BSBMTCT), the Children\u2019s cancer and Leukaemia Group (CCLG), and British Infection Association (BIA). J Infect 86(1):1\u20138. https:\/\/doi.org\/10.1016\/j.jinf.2022.11.005","journal-title":"J Infect"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-07139-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07139-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07139-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T09:20:13Z","timestamp":1786785613000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-07139-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,16]]},"references-count":37,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["7139"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-07139-1","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,16]]},"assertion":[{"value":"27 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"These data were derived from SOPs, financial data, and hospital staff expert interviews and do not report individual patient data; therefore, ethics approval was not required.","order":1,"name":"Ethics","label":"Ethics and Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JW reports travel expenses from Pierre Fabre and Gilead-Kite; honorarium from Takeda. MG is the scientific director of software-based academic training with a university certificate for Certified Workflow Manager in Health Care with the ClipMed\n                      \u00ae\n                      PPM application and was remunerated by J&J Innovative Medicine for this analysis. He also discloses connections to J&J Innovative Medicine EMEA in the form of a mandate to conduct the SPGA.GH reports consultancy from AbbVie, ADC, AstraZeneca, BeiGene, Bristol Myers Squibb, Gilead-Kite, Incyte, Janssen, Lilly, Miltenyi Biotech, MSD, Novartis, Pierre Fabre, Roche, and Sobi; honoraria from AbbVie, ADC Therapeutics, AstraZeneca, BeiGene, Bristol Myers Squibb, Gilead-Kite, Incyte, Janssen, Lilly, Miltenyi Biotech, MSD, Novartis, Roche, and Sobi; research funding (to institution) from AbbVie, Gilead-Kite, Janssen, and Lilly; and travel grants from Incyte, J&J, and Pierre Fabre. JO is the head of data validation and analysis in this project using the ClipMed\n                      \u00ae\n                      PPM application and is an employee of IWiG. IWiG was remunerated by J&J Innovative Medicine for this analysis.NSR, FR, and AO report no disclosures.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors certify that they meet the ICMJE criteria for authorship.","order":3,"name":"Ethics","label":"Authorship confirmation","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation or approval of the manuscript.","order":4,"name":"Ethics","label":"Role of the funder\/sponsor","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"337"}}